The UK and US have announced a landmark trade agreement that will maintain zero import taxes on UK medicine shipments being sold in the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has committed to increase funding on medicines through the public health system. This pledge guarantees that tariffs on these key exports will be held at zero for a period of 36 months.
This agreement comes after previous statements to hike import taxes on branded drug products, with potential rates discussed up to one hundred percent.
"This agreement with the Britain strengthens the international landscape for new treatments and brings long-overdue fairness to U.S.–U.K. medicine commerce," a release noted.
Economic Significance
Pharmaceuticals are one of the the United Kingdom's largest exports to the America, which is easily the primary market for leading UK drugmakers.
Statistics show that in the one-year period to the end of last September, the UK exported medicines valued at billions to the US. This figure made up 17.4% of total UK exports in that period.
"This deal protects work, stimulates capital expenditure and paves the way for the UK to establish itself as a international leader for life sciences," a minister commented.
Key UK Commitments
The pact includes several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new medicines to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to raise total NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to control costs will be limited at fifteen percent. Previously, refunds exceeded twenty percent.
Industry Background
This agreement follows a long-running tension between the drug companies and the ministers over spending levels and approval rates.
These tensions were intensified by arguments that American customers were paying a premium for the identical medicines than patients in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been paused or cancelled, while substantial investments have been announced toward American operations.
A senior figure stated that the NHS must spend more on drugs, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the last ten years.
